Wanbury Ltd (Pharma - API) — fundamental analysis, earnings data, and key metrics. PE: 18.4. ROE: 76.5%. This stock is not currently in the Nifty 500 momentum outperformers list.
Based on Q3 FY26 earnings • Updated Feb 22, 2026
What: Commercial shipments of high potent anaesthetic API to European customers now underway
Impact: +₹25 Cr revenue
“Mr. Mohan Rayana: 'achieved commercial invoicing and shipment to European customers for high potent anaesthetic API from its cutting-edge Tanaku facility in Q3FY26'”
What: Antidiabetic, Anticoagulant, Cough suppressant and Antidepressant products entering market
Impact: +₹45 Cr revenue
“Management: 'well positioned for growth with upcoming new product launches including Antidiabetic, Anticoagulant, Cough suppressant and Antidepressant products'”
What: C-Red nutritional supplement driving formulations segment profitability
Impact: +₹17.5 Cr revenue
“Management: 'formulations business remained EBITDA positive with good results from the recent launch of nutritional supplement C-Red and other products'”
Earnings deceleration risks from management commentary
Trigger: Delays in regulatory approvals
Impact: -200 bps margin impact
Management view: Not explicitly addressed but implied focus on successful commercialization
Monitor: New product launch timelines
Trigger: Increased competitor capacity
Impact: -150 bps margin impact
Management view: Not explicitly addressed in available materials
Monitor: Quarterly margin trends
Key quotes from recent conference calls
“higher API volumes, improved capacity utilization, and operational efficiency gains across both API and formulations business segments — Management Commentary”
“EBITDA margin expanded significantly to 16.5% from 11.0% year-on-year, led by operating leverage, better procurement strategies, higher product yields and enhanced solvent recovery systems — Management Commentary”
“The company is well positioned for growth with upcoming new product launches including Antidiabetic, Anticoagulant, Cough suppressant and Antidepressant products — Mr. Mohan Rayana, Director”
Forward-looking targets from management for 2-4 quarters
Key Milestones
• Tanaku facility ramp-up
• New product launches
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Feb 22, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Wanbury Ltd's latest quarterly results (Dec 2025) show
Wanbury Ltd's current PE ratio is 18.4x.
Wanbury Ltd's price-to-book ratio is 12.5x.
Wanbury Ltd's fundamental strength based on key financial ratios
Wanbury Ltd has a debt-to-equity ratio of N/A.
Wanbury Ltd's return ratios over recent years
Wanbury Ltd's operating cash flow is positive (FY2025).
Wanbury Ltd currently does not pay a significant dividend (yield 0.00%).
Wanbury Ltd's shareholding pattern (Dec 2025)
Wanbury Ltd's promoter holding has decreased recently.
Wanbury Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Wanbury Ltd has 3 key growth catalysts identified from recent earnings analysis
Wanbury Ltd has 2 key risks worth monitoring
In Q3 FY26, Wanbury Ltd's management highlighted
Wanbury Ltd's management has provided the following forward guidance for 2-4 quarters
Based on quantitative research signals, here is why Wanbury Ltd may be worth studying
Wanbury Ltd investment thesis summary:
Wanbury Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
